VTAK VS GRI Stock Comparison

Performance

VTAK
10/100

VTAK returned -27.27% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.

GRI
10/100

GRI returned -91.59% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

VTAK
75/100

4 analysts offer 12-month price targets for VTAK. Together, they have an average target of 0, the most optimistic target put VTAK at 0 within 12-months and the most pessimistic has VTAK at 0.

GRI

"Analyst Price Targets" not found for GRI

Earnings

VTAK
100/100

VTAK has missed earnings 0 times in the last 20 quarters.

GRI

"Earnings" not found for GRI

Volatility

VTAK
48/100

VTAK has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

GRI
36/100

GRI has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.

Profit

VTAK

"Profit" not found for VTAK

GRI
20/100

Out of the last 4 quarters, GRI has had 1 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Catheter Precision, Inc. Summary

Healthcare

Medical - Devices

Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.

GRI Bio, Inc. Common Stock Summary

Nasdaq / GRI

Healthcare

Biotechnology

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Power up your portfolio